Comparing MK-1045 Plus Rituximab to Standard Chemotherapy and Rituximab in Adults With Follicular Lymphoma

What this Trial Is About

Researchers are studying new treatments for follicular lymphoma FL, a type of cancer affecting the lymphatic system. This trial evaluates the safety and effectiveness of a new immunotherapy called MK-1045 combined with rituximab, compared to the standard treatment of rituximab plus chemotherapy. The study aims to see if MK-1045 with rituximab can better control the cancer, help it go away, and extend the time patients live without their disease worsening. Participants in this trial receive MK-1045 through weekly intravenous infusions at increasing doses for up to about 12 months, alongside rituximab infusions every 4 weeks for up to 6 months. The comparison group receives physician-chosen chemotherapy treatments combined with rituximab over similar periods. Different chemotherapy options include bendamustine or combinations of cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. The study is divided into two parts Part 1 focuses on finding the right MK-1045 dose and safety, and Part 2 compares MK-1045 plus rituximab to standard chemotherapy plus rituximab. Throughout the study, participants undergo regular evaluations including scans to measure cancer size and tests to monitor safety and drug levels. Researchers track side effects, treatment tolerability, cancer response, and quality of life using questionnaires. The main outcomes include adverse events, response rates, and progression-free survival over several years. The trial lasts multiple years with monitoring up to about 5 years to understand long-term effects and benefits of the treatments.

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)